Epigenetics
Epigenetics is typically defined as the study of heritable changes in gene expression that are not due to changes in DNA sequence. Epigenetic modifications of chromatin have been shown to play a major role in cancer onset and development. Acetylation and methylation are the most-studied chromatin marks, having fundamental functions in the epigenetic regulation of gene expression[1],[2].
Epigenetic modification of histones is a reversible process. Histone acetyltransferases (HATs) are the enzymes responsible for the introduction of acetyl groups on histones, whereas methyl groups can be introduced both on DNA and histones by DNA methyltransferases (DNMTs) and histone methyltransferases (HMTs)[3]. The removal of methyl and acetyl groups is enzymatically mediated by the action of histone demethylases (HDMs) and histone deacetylases (HDACs), respectively. In turn, epigenetic marks can be recognized by and bound to specific protein domains, such as bromodomain and malignant brain tumor (MBT). These complexes are important intermediates in the epigenetic regulation of gene expression[4].
Axon Medchem offers a wide selection of bioactive small molecules to modulate epigenetic mechanisms, serving researchers in their objective to investigate biological consequences of chromatin modifications and develop new drugs for cancer treatment.
Epigenetic products Library
For your convenience, you can order a library of all of our Epigenetics related products. Make your personal library by cherry picking products of your interest from our comprehensive list (125 products), or order all together not to miss any. The libraries will be shipped as 10 mM solutions (in DMSO, 250 µL of each selected Axon Ligand™) on a 96-well microtiter plate with a clear map of its contents.
Simply download our comprehensive list of epigenetics products below (Microsoft Excel (.xls)), check the products to be included, and return your list to order the library of your preference.
 Axon Ligands™ - Epigenetics Library.xls |
Modifiers of Histone
|
Histone Demethylase (LSD/Jumonji C) |
Histone Deacetylase (HDAC) |
|
SET domain lysine Methyltransferase (G9a/EZH2) |
Histone Deacetylase (SIRT) |
|
Arginine Methyltransferase (PRMT) |
|
|
DNA Methyltransferase (DNMT) |
|
Recognition of modified Histone
|
Recognition of Acetylated Lysine (Bromodomains) |
Recognition of Metylated Lysine (Kme/MBT) |
[1] Epigenetics in Cancer. Manel Esteller.N Engl J Med 2008; 358, 1148-1159.
[2] Epigenetic protein families: a new frontier for drug discovery. CH Arrowsmith et al. Nature 2012, 11, 384-400.
[3] Histone acetyltransferases as emerging drug targets. FJ Dekker and HJ Haisma. Drug Discov. Today 2009, 14(19-20), 942-948.
[4] Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family. Filippakopoulos, P. et al. Cell 2012, 149, 214-231
.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 1989 | (+)-JQ1 |
Potent and selective BET bromodomain inhibitor |
€60.00 | |
| 3822 | (+)-JQ1 carboxylic acid | (+)-JQ1 derivative; PROTAC precursor | €110.00 | |
| 3873 | (-)-JQ-1 | Inactive enantiomer of (+)-JQ1 | €120.00 | |
| 2537 | 1,5-Isoquinolinediol | PARP1 inhibitor and neuroprotective agent | €50.00 | |
| 1496 | 3-Aminobenzamide | Competitive small molecule inhibitor of PARP | €40.00 | |
| 2705 | A-196 | Potent and selective inhibitor of SUV4-20 | €105.00 | |
| 3696 | ABBV-075 | Highly potent and orally bioavailable BET bromodomain (BRD) inhibitor | €110.00 | |
| 3956 | ABBV-744 | First-in-class highly BDII (Bromodomain II)-selective BET bromodomain inhibitor | Inquire | |
| 3039 | ACY-241 | Selective and orally available HDAC6 inhibitor | €120.00 | |
| 1529 | AG 014699 | PARP1 inhibitor | €60.00 | |
| 1378 | AG 490 | JAK2 inhibitor | €65.00 | |
| 2746 | AG-120 | IDH1 mutant enzyme inhibitor | €125.00 | |
| 2745 | AG-221 | IDH2 mutant enzyme inhibitor | €95.00 | |
| 2274 | AGI 6780 | Potent and selective inhibitor of the tumor-associated mutant IDH2 (R140Q) | €90.00 | |
| 2389 | AICAR | Potent AMPK activator and inducer of differentiation of NSCs | €45.00 | |
| 2269 | AK 1 | Potent inhibitor of SIRT with good selectivity for SIRT2 over SIRT1 and SIRT3 | €90.00 | |
| 2270 | AK 7 | Potent, brain-permeable and selective inhibitor of SIRT2 | €90.00 | |
| 3834 | Alantolactone | STAT3 inhibitor; NLRP3 inhibitor | €90.00 | |
| N0002 | Althiomycin | Antibacterial | Inquire | |
| 1783 | AMG 900 | Aurora inhibitor (non-specific) | €110.00 | |
| 2863 | AMI-1 | Inhibitor of PRMT | €99.00 | |
| 2468 | ANA 12 | Selective TrkB antagonist with anxiolytic and antidepressant activity in mice | €90.00 | |
| 1490 | Anacardic acid A | HAT inhibitor | €60.00 | |
| 2394 | AR-42 | HDAC inhibitor | €125.00 | |
| 3944 | ARV-825 | Potent and selective protein BRD4 degrader | Inquire | |
| 2219 | AT 9283 | Multitargeted kinase inhibitor (Aurora A/B, JAK2/3, and BCR-Abl) | €85.00 | |
| 1597 | Aurora A inhibitor I | Aurora A inhibitor | €125.00 | |
| 1630 | Aurora A inhibitor II | Aurora A inhibitor | €125.00 | |
| 5052 | Axon Ligands™ Epigenetic compound library | Axon Ligands™ Epigenetic compound library | Inquire | |
| 1778 | AZ 960 | JAK2 inhibitor | €95.00 | |